An interventional study of Aerobic training and Usual Care in PARKINSON DISEASE (Disorder), sponsored by Raphael Mendes Ritti Dias. Recruiting at 1 site in Brazil. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Raphael Mendes Ritti Dias · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Parkinson Disease with a site in Brazil — 19 open to participants now, 22 under way, 1 of them phase 3. Parkinson Disease · Brazil.
Among the 103 studies in Parkinson Disease with a site in Brazil, this one is the 37th largest by planned enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2026, is one of 81 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 98th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →19 of the 103 studies in Parkinson Disease with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Metodista de Piracicaba · Sites in Brazil
Ages 50–80
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18+
Universidade Federal de Pernambuco · Sites in Brazil
Ages 40+
Hoffmann-La Roche · Sites in Brazil, United States, Australia and 14 more countries
Ages 50–85
Federal University of Rio Grande do Sul · Sites in Brazil
Ages 50–80
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 9
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 34 across the 95 interventional studies, 322 across the 8 observational. Of the 53 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 103 have an industry lead sponsor. The 10 most frequent:
Raphael Mendes Ritti Dias is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Raphael Mendes Ritti Dias has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Parkinson Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488026Universidade Federal de PernambucoEffects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease | 2026-11 |
| NCT07172698Federal University of Health Science of Porto AlegreEffects of a Multicomponent Protocol With Emphasis on Muscle Power Training on Bradykinesia in Individuals With Parkinson's Disease | 2026-12-01 |
| NCT06921122Hospital de Clinicas de Porto AlegreUse Of A Tongue Strength Training Device And Its Relationship With Speech In Patients With Parkinson's Disease | 2026-12-20 |
| NCT06815302Oregon Health and Science UniversityTURN-IT FOG: Improving Turning and Freezing of Gait in People With PD | 2026-12-31 |
| NCT07567599Federal University of Minas GeraisDeep Brain Stimulation in Parkinson's Disease: Motor and Functional Outcomes | 2027-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 103 studies in Parkinson Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial will investigate the effects of a 12-week supervised aerobic training program on cerebrovascular function, peripheral vascular health, cardiovascular autonomic modulation, cognition, non-motor symptoms, sleep, mood, gait biomechanics, quality of life, and body composition in patients with Parkinson's disease (Hoehn \& Yahr stages 1-3). Participants will be randomly allocated to aerobic training or usual care.
This is a parallel-group randomized controlled trial Participants (n=40) diagnosed with Parkinson's disease, stages 1-3 on Hoehn \& Yahr scale, will be randomly allocated (1:1 block randomization) to:
The intervention will last 12 weeks, 3 sessions/week Pre and post-intervention assessments will include:
All experimental sessions will be performed in the "on" medication state
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will perform supervised aerobic training on a cycle ergometer, 3 times per week for 12 weeks, 40 minutes per session, at perceived exertion 12-13 on Borg scale.
Behavioral: Aerobic training
Participants will maintain their usual clinical care and daily activities without structured exercise intervention.
Behavioral: Usual Care
Aerobic Exercise Training
Usual Care
Change in Cerebrovascular Reactivity
Breath-holding index (dimensionless) assessed by transcranial Doppler
Time frame: Baseline and 12 weeks
Change in Neurovascular Coupling at 12 Weeks.
Measured by relative (%) changes in middle cerebral artery blood flow velocity during standardized cognitive tasks (Stroop Color-Word Test, Trail Making Test A and B, and silent reading protocol) using transcranial Doppler ultrasound.
Time frame: Baseline and 12 weeks
Change in Dynamic Cerebral Autoregulation
Transfer function gain and phase (0.02-0.4 Hz frequency bands).
Time frame: Baseline and 12 weeks
Change in Acute Cerebral Blood Flow Response to Exercise
Change in middle cerebral artery velocity during 6-minute aerobic bout.
Time frame: Baseline and 12 weeks
Change in Brachial Artery Endothelial Function
Flow-mediated dilation (FMD, %) of the brachial artery assessed by high-resolution vascular ultrasound according to current guidelines.
Time frame: Baseline and 12 weeks
Change in Brachial Artery Baseline Diameter
Resting brachial artery diameter (mm) measured by vascular ultrasound
Time frame: Baseline and 12 weeks
Change in Carotid Intima-Media Thickness
Common carotid artery intima-media thickness (mm) assessed by B-mode ultrasound.
Time frame: Baseline and 12 weeks
Change in Resting Blood Pressure
Systolic and diastolic blood pressure (mmHg).
Time frame: Baseline and 12 weeks
Change in Resting Heart Rate
Heart rate (beats per minute).
Time frame: Baseline and 12 weeks
Change in SDNN
SDNN derived from beat-to-beat recordings at rest.
Time frame: Baseline and 12 weeks
Change in Low Frequency Power
Low-frequency power (ms²) derived from spectral analysis.
Time frame: Baseline and 12 weeks
Change in Cognitive Function
Assessed with Montreal Cognitive Assessment that provides a score
Time frame: Baseline and 12 weeks
Change in Executive Function and Attention
Assessed with Trail Making Test Part A and Part B (time to completion, seconds).
Time frame: Baseline and 12 weeks
Change in Non-Motor Symptoms
Assessed with Non-Motor Symptoms Scale that provides a score. Higher scores indicate greater symptom burden.
Time frame: Baseline and 12 weeks
Change in Parkinson Disease Severity
Assessed with the Unified Parkinson's Disease Rating Scale (UPDRS total score).
Time frame: Baseline and 12 weeks
Change in Anxiety Severity
Assessed with the Parkinson Anxiety Scale total score (0-48). Higher scores indicate greater anxiety severity.
Time frame: Baseline and 12 weeks
Change in Depressive Symptoms
Assessed with Geriatric Depression Scale total score (0-15). Higher scores indicate greater depressive symptom severity.
Time frame: Baseline and 12 weeks
Change in Apathy
Assessed with Apathy Inventory total score (0-12). Higher scores indicate greater apathy.
Time frame: Baseline and 12 weeks
Change in Fatigue
Parkinson Fatigue Scale total score (range: 16-80). Higher scores indicate greater fatigue severity.
Time frame: Baseline and 12 weeks
Change in Sleep Quality
Assessed with Parkinson's Disease Sleep Scale total score (0-150). Lower scores indicate worse sleep quality.
Time frame: Baseline and 12 weeks
Change in Pain
Assessed using a Numeric Rating Scale (0-10). Higher values indicate higher pain
Time frame: Baseline and 12 weeks
Change in Quality of Life
Assessed with Parkinson's Disease Questionnaire-8 (PDQ-8 total score).
Time frame: Baseline and 12 weeks
Change in Gait Speed
Gait speed (meters/second) assessed during overground walking using motion capture analysis.
Time frame: Baseline and 12 weeks
Change in Gait Kinematics
Joint angles (degrees) of hip, knee, and ankle during walking assessed by 3D motion capture.
Time frame: Baseline and 12 weeks
Change in Joint Moments During Walking
Joint moments (Nm/kg) of the hip, knee, and ankle during walking assessed using force platform analysis.
Time frame: Baseline and 12 weeks
Change in Muscle Thickness
Quadriceps muscle thickness (mm) assessed by B-mode ultrasound at standardized anatomical landmarks.
Time frame: Baseline and 12 weeks
Change in Subcutaneous Adipose Tissue Thickness
Subcutaneous fat thickness (mm) assessed by B-mode ultrasound at standardized anatomical landmarks.
Time frame: Baseline and 12 weeks
Change in RMMSD
RMSSD (ms) derived from beat-to-beat recordings at rest.
Time frame: Baseline and 12 weeks
Change in High Frequency Power
High-frequency power (ms²)derived from spectral analysis
Time frame: Baseline and 12 weeks
Change in Low Frequency/High Frequency ratio
Low-frequency/high-frequency ratio derived from spectral analysis
Time frame: Baseline and 12 weeks
Change in Cadence
Cadence (steps/minute) assessed during overground walking using motion capture analysis.
Time frame: Baseline and 12 weeks
Change in Stride Length
Stride length (meters) assessed during overground walking using motion capture analysis.
Time frame: Baseline and 12 weeks
Change in Double Support Time
Double support time (% of gait cycle) assessed during overground walking using motion capture analysis
Time frame: Baseline and 12 weeks
Change in Joint Powers During Walking
Joint powers (W/kg) of the hip, knee, and ankle during walking assessed using force platform analysis.
Time frame: Baseline and 12 weeks
Plan to share: Yes — Anonymized datasets will be avaliable after the completion of the study and publication of main results
Time frame: 6 months after the publication
Access criteria: Open acess
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 16 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Raphael Mendes Ritti Dias